Ironwood Pharmaceuticals Inc (IRWD)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

100 SUMMER STREET, SUITE 2300 BOSTON, MA 02110

Ironwood Pharmaceuticals, Inc. discovers, develops, and commercializes medicines targeting therapeutic needs. The company is developing Linaclotide, a first-in-class compound that is in confirmatory Phase III clinical trials for the treatment of irritable bowel syndrome with constipation, chronic constipation, and other lower gastrointestinal conditions. It also focuses on one Phase I pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. The company has a collaboration agreement with Forest Laboratories, Inc. to jointly develop and commercialize linaclotide in North America; a license agreement with Almirall, S.A. to develop and commercialize linaclotide in Europe; a license agreement with Astellas Pharma Inc. that provides Astellas Pharma with the right to develop and commercialize linaclotide in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Data based on most recent fiscal year report
Market Cap1.965 Billion Shares Outstanding156.82 Million Avg Volume2.146 Million
1-Yr BETA vs S&P TR1.351 Current Ratio2.23 Quick Ratio2.23
View SEC Filings from IRWD instead.

View recent insider trading info

 
Ironwood Pharmaceuticals Inc Chart by YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Check out our reporting and analysis

Funds Holding IRWD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IRWD BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

88.9 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

88.9 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MCCOURT THOMAS A PRESIDENT

  • Officer
 225,239 2020-01-24 7

CURRIE MARK G

  • Director
 549,272 2020-01-23 8

RIDGEBACK CAPITAL INVESTMENTS L.P.

RIDGEBACK CAPITAL INVESTMENTS LTD.

RIDGEBACK CAPITAL MANAGEMENT LP

  • 10% Owner
 4,553,092 2020-01-14 0

HIGGINS MICHAEL J

  • Director
 0 2020-01-09 0

FMR LLC

  • 10% Owner
  • SEE REMARK 1
 18,375,638 2020-01-02 0

GILBERT HALLEY E CHIEF ADMIN OFFICER & SVP

  • Officer
 281,319 2019-12-16 5

CONSYLMAN GINA SVP, CFO & TREASURER

  • Officer
 215,288 2019-12-16 6

MACDONALD KELLY CHIEF ACCOUNTING OFFICER

  • Officer
 86,567 2019-12-16 4

DREYFUS ANDREW

  • Director
 85,342 2019-12-13 4

HECHT PETER M CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 0 2019-11-22 2

HUYETT WILLIAM CHIEF FINANCIAL OFFICER

  • Officer
 0 2019-11-22 1

FANUCCI MARSHA

  • Director
 0 2019-11-20 2

WILLIAMS DOUGLAS E

  • Director
 0 2019-11-13 1

ROBERTS BRYAN E

  • Director
 300,000 2019-09-16 0

EBERSMAN DAVID A

  • Director
 0 2019-08-05 0

SCHULMAN AMY W

  • Director
 0 2019-07-01 2

MCHUGH JULIE

  • Director
 109,337 2019-06-05 3

OLANOFF LAWRENCE S

  • Director
 58,259 2019-06-05 3

MCGUIRE TERRANCE

  • Director
 0 2019-06-01 2

CONRADES GEORGE H

  • Director
 0 2019-06-01 0

OWENS EDWARD P

  • Director
 222,234 2019-05-29 1

DUANE JON R

  • Director
 25,701 2019-05-29 3

KESSLER MARLA L

  • Director
 25,701 2019-05-29 3

MOUKHEIBIR CATHERINE

  • Director
 25,701 2019-05-29 3

SHAW DAVID EVANS

  • Director
 2,150,523 2019-04-16 0

MALLON MARK CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 311,409 2019-04-01 1

GRANEY THOMAS CHIEF FINANCIAL OFFICER

  • Officer
 12,430 2018-10-01 0

WALSH CHRISTOPHER T PHD

  • Director
 374,525 2017-03-15 0

COOK JOSEPH C JR

  • Director
 0 2015-06-18 0

FMR LLC

FIL LTD

  • EDWARD C. JOHNSON 3DEDWARD C. JOHNSON 3D
 No longer subject to file 2013-03-28 0

VENROCK ASSOCIATES

VENROCK ASSOCIATES II LP

VENROCK ENTERPRENEURS FUND LP

VR MANAGEMENT LLC

  • 10% Owner
 No longer subject to file 2013-03-15 0

VHCP CO-INVESTMENT HOLDINGS, LLC

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP MANAGEMENT, LLC

VENROCK ASSOCIATES V LP

VENROCK PARTNERS V L P

VENROCK MANAGEMENT V, LLC

VENROCK PARTNERS MANAGEMENT V, LLC

HOVE ANDERS D

  • 10% Owner
 No longer subject to file 2013-03-15 0

VR MANAGEMENT LLC

  • 10% Owner
 42,667 2011-03-31 0

VENROCK ASSOCIATES

VENROCK ASSOCIATES II LP

VENROCK ENTERPRENEURS FUND LP

VENROCK MANAGEMENT LLC

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP CO-INVESTMENT HOLDINGS, LLC

VHCP MANAGEMENT, LLC

VR MANAGEMENT LLC

HOVE ANDERS D

  • 10% Owner
 8,731,321 2010-02-02 0

MILLER GINA BORNINO

  • Director
 770,952 2010-02-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MCCOURT THOMAS A - Officer PRESIDENT

2020-01-24 S 20,000 $12.71 d 225,239 225,239.00 direct yes

MCCOURT THOMAS A - Officer PRESIDENT

2020-01-24 M 20,000 $10.02 a 245,239 225,239.00 direct

MCCOURT THOMAS A - Officer PRESIDENT

2020-01-24 M 20,000 d 0 225,239.00 direct

CURRIE MARK G - Director

2020-01-23 S 60,000 $12.59 d 549,272 549,272.00 direct yes

CURRIE MARK G - Director

2020-01-23 M 60,000 $9.12 a 609,272 549,272.00 direct

CURRIE MARK G - Director

2020-01-23 M 60,000 d 47,707 549,272.00 direct

CURRIE MARK G - Director

2020-01-16 S 8,888 $12.80 d 549,272 549,272.00 direct yes

CURRIE MARK G - Director

2020-01-16 M 8,888 $10.02 a 558,160 549,272.00 direct

CURRIE MARK G - Director

2020-01-16 M 8,888 d 0 549,272.00 direct

CURRIE MARK G - Director

2019-12-17 G 500 d 549,272 549,272.00 direct

MACDONALD KELLY - Officer CHIEF ACCOUNTING OFFICER

2019-12-16 A 8,230 a 86,567 86,567.00 direct

CURRIE MARK G - Director

2019-12-16 G 1,837 d 549,772 549,272.00 direct

MCCOURT THOMAS A - Officer PRESIDENT

2019-12-16 A 115,220 a 224,959 224,959.00 direct

CONSYLMAN GINA - Officer SVP, CFO & TREASURER

2019-12-16 A 41,150 a 215,288 215,288.00 direct

GILBERT HALLEY E - Officer CHIEF ADMIN OFFICER & SVP

2019-12-16 A 41,150 a 281,319 281,319.00 direct

DREYFUS ANDREW - Director

2019-12-13 A 1,270 a 85,342 85,342.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments